[email protected]/(408) 457-3700

About Theracle

Gliomas represent a clear unmet medical need as approximately 50% of patients die within 18 months of a diagnosis, and current treatments are of limited effectiveness. According to the American Cancer Society, about 13,000 will die from brain and nervous system cancers each year. In addition, the five year survival rate is less than 20%. Current drug therapies have been limited due to systemic side effects or the inability of drugs to effectively cross the blood brain barrier. Theracle's novel approach has the potential to extend the lives of these patients while limiting systemic side effects. Theracle is currently in stealth mode.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

San Antonio
Biotechnology, Medical Devices
Therapeutic Areas:
CNS / Neurology, Oncology